The advanced glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension

被引:63
作者
Busch, Martin [1 ]
Franke, Sybille
Wolf, Gunter
Brandstaedt, Antje
Ott, Undine
Gerth, Jens
Hunsicker, Lawrence G.
Stein, Guenter
机构
[1] Univ Jena, Dept Internal Med 3, D-07740 Jena, Germany
[2] Univ Jena, Inst Med Stat & Comp Sci, D-07740 Jena, Germany
[3] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
关键词
chronic renal failure; cardiovascular risk; advanced glycation end-products; N-epsilon-carboxymethyllysine; type; 2; diabetes; Irbesartan in Diabetic Nephropathy Trial;
D O I
10.1053/j.ajkd.2006.07.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Advanced glycation end products (AGEs) are implicated in the pathogenesis of vascular damage, especially in patients with diabetes and renal insufficiency. The oxidatively formed AGE N-epsilon-carboxymethyllysine (CML) is thought to be a marker of oxidative stress. Methods: Four hundred fifty patients with type 2 diabetes and nephropathy from the Irbesartan in Diabetic Nephropathy Trial cohort (mean age, 58 +/- 8.2 years; 137 women, 313 men) with a mean glomerular filtration rate of 48.2 mL/min (0.80 mL/s; Modification of Diet in Renal Disease formula) were followed up for 2.6 years. Serum CML was measured by using an enzyme-linked immunosorbent assay. Relationships between CML levels, traditional risk factors, and cardiovascular and renal events were tested in Cox proportional hazards models. Results: Mean serum CML level was 599.9 +/- 276.0 ng/mL, and mean hemoglobin A(1c) level was 7.5%+/- 1.6%. One hundred forty-three first cardiovascular events occurred during follow-up; 74 patients died, 44 of cardiovascular causes. Final multivariate analysis showed age (relative risk [RR], 1.87; confidence interval [CI], 1.13 to 3.11; P=0.016 for the highest compared with lowest quartile), history of prior cardiovascular events (RR, 1.96; CI, 1.35 to 2.85; P<0.0005), and 24-hour urinary albumin-creatinine ratio (RR, 1.29; CI, 1.11 to 1.50 per doubling; P<0.0005) to be independent risk factors for a first cardiovascular event, but not CML level. CML level also did not correlate significantly with renal outcome. Conclusion: Serum CML level could not be identified as an independent risk factor for cardiovascular or renal outcomes in the examined population. This suggests that traditional risk factors might have a more important role for these end points or that other AGE compounds, as well as tissue AGE levels, might be of greater relevance compared with serum levels, which remains open to further study.
引用
收藏
页码:571 / 579
页数:9
相关论文
共 41 条
[1]
ANAVEKAR NS, 2004, KIDNEY INT S, V92, P850
[2]
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes [J].
Basta, G ;
Schmidt, AM ;
De Caterina, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :582-592
[3]
Role of oxidative stress in diabetic complications - A new perspective on an old paradigm [J].
Baynes, JW ;
Thorpe, SR .
DIABETES, 1999, 48 (01) :1-9
[4]
Glycoxidation and lipoxidation in atherogenesis [J].
Baynes, JW ;
Thorpe, SR .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 28 (12) :1708-1716
[5]
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy [J].
Berl, T ;
Hunsicker, LG ;
Lewis, JB ;
Pfeffer, MA ;
Porush, JG ;
Rouleau, JL ;
Drury, PL ;
Esmatjes, E ;
Hricik, D ;
Parikh, CR ;
Raz, I ;
Vanhille, P ;
Wiegmann, TB ;
Wolfe, BM ;
Locatelli, F ;
Goldhaber, SZ ;
Lewis, EJ .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) :542-549
[6]
AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept [J].
Bierhaus, A ;
Hofmann, MA ;
Ziegler, R ;
Nawroth, PP .
CARDIOVASCULAR RESEARCH, 1998, 37 (03) :586-600
[7]
Elevated serum levels of Nε-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema [J].
Boehm, BO ;
Schilling, S ;
Rosinger, S ;
Lang, GE ;
Lang, GK ;
Kientsch-Engel, R ;
Stahl, P .
DIABETOLOGIA, 2004, 47 (08) :1376-1379
[8]
Potential cardiovascular risk factors in chronic kidney disease:: AGEs, total homocysteine and metabolites, and the C-reactive protein [J].
Busch, M ;
Franke, S ;
Müller, A ;
Wolf, M ;
Gerth, J ;
Ott, U ;
Niwa, T ;
Stein, G .
KIDNEY INTERNATIONAL, 2004, 66 (01) :338-347
[9]
Chalmers J, 1999, J HYPERTENS, V17, P151
[10]
The serum concentration of the advanced glycation end-product N-epsilon-(carboxymethyl)lysine is increased in uremia [J].
Degenhardt, TP ;
Grass, L ;
Reddy, S ;
Thorpe, SR ;
Diamandis, EP ;
Baynes, JW .
KIDNEY INTERNATIONAL, 1997, 52 (04) :1064-1067